Group 1 - The company has completed the acquisition of a controlling stake in REGEN, with the domestic product "Zhen Ai Su Fei" already launched for sale, and attention is on the sales ramp-up during the transition period [1] - The company has received approval for Minoxidil topical solution, and it is expected that 2026 will see a concentrated launch of new pipelines such as botulinum toxin, with a focus on the progress of these new products in the domestic market [1] - The company has completed its first cosmetic raw material filing, with the core ingredient "Glycyrrhetinic Acid A" sourced from the Chinese herb licorice, which can be used as a skin protectant and moisturizer in cosmetics [1] Group 2 - The traditional product segment is under short-term pressure due to low market sentiment and intensified competition, with Q3 revenue expected to continue its downward trend [2] - For the first three quarters of 2025, revenue was 1.865 billion, down 21.49%, and net profit attributable to the parent company was 1.093 billion, down 31.05% [2] - In Q3 2025, revenue was 566 million, down 21.27%, and net profit attributable to the parent company was 304 million, down 34.61% [2] Group 3 - The company’s performance remains under pressure due to low industry sentiment and increased competition, with a focus on the sales ramp-up of "Zhen Ai Su Fei" during the transition period [3] - The new REGEN factory in South Korea has successfully commenced production, expected to release incremental capacity this year and expand into markets in the Middle East and Southeast Asia [3] - The company is anticipated to experience a concentrated launch of new pipelines in 2026, with attention on the progress of these new products and their market release rhythm [3]

从资金流向上来看，当日医疗美容板块主力资金净流出5875.57万元，游资资金净流入1690.61万元，散户 资金净流入4184.96万元。医疗美容板块个股资金流向见下表： 证券之星消息，11月24日医疗美容板块较上一交易日上涨0.27%，*ST美谷领涨。当日上证指数报收于 3836.77，上涨0.05%。深证成指报收于12585.08，上涨0.37%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 4.07 | 4.63% | 28.52万 | | 1.15亿 | | 688363 | 华熙生物 | 49.78 | 1.86% | 1.87万 | | 9268.75万 | | 300896 | 爱美客 | 66'56 | -1.36% | 2.41万 | | 3.52亿 | | 920982 | 锦波生物 | 216.59 | -1.55% | 7336.92 | | 1.60亿 | | 代码 | 名称 | 主力净流 ...

Investment Rating - The report maintains a "Positive" outlook on the beauty and personal care industry, highlighting robust demand and the continued rise of domestic brands [2]. Core Insights - The beauty care industry is experiencing a stable demand phase, with domestic leading brands expected to grow during the industry consolidation period [3]. - The cosmetics sector showed resilience during the off-peak season, with retail sales reaching 98.2 billion yuan from July to September, reflecting a single-digit year-on-year growth and an acceleration compared to the first half of 2025 [2][3]. - The report emphasizes the strong performance of domestic brands during the Double 11 shopping festival, with Proya ranking first in Tmall's beauty sales [2][11]. Summary by Sections Cosmetics Sector Performance - The cosmetics sector's key A-share companies reported an average revenue growth rate of around 3% in Q3 2025, with overall improvement in net profit [2]. - Proya's cumulative revenue for the first three quarters of 2025 was 7.098 billion yuan, a year-on-year increase of 1.89%, while its Q3 revenue was 1.736 billion yuan, down 11.63% year-on-year [16]. - Other notable performances include: - Ruifucheng: Q1-Q3 revenue of 2.138 billion yuan, up 85.3% year-on-year, with Q3 revenue of 819 million yuan, up 123.4% year-on-year [16]. - Marubi: Q1-Q3 revenue of 2.45 billion yuan, up 25.5% year-on-year, with Q3 revenue of 686 million yuan, up 14.28% year-on-year [16]. Medical Aesthetics Sector Performance - The medical aesthetics sector showed slight fatigue but experienced marginal improvements in Q3 2025 [2]. - Notable performances include: - Aimeike: Q1-Q3 revenue of 1.865 billion yuan, down 21.49% year-on-year, with Q3 revenue of 566 million yuan, down 21.27% year-on-year [2]. - Longzi: Q1-Q3 revenue of 4.328 billion yuan, up 0.9% year-on-year, with Q3 revenue of 1.539 billion yuan, up 11.9% year-on-year [2]. Investment Recommendations - The report recommends focusing on companies with a well-established channel and brand matrix, such as Maogeping, Shangmei, and Shanghai Jahwa, which are expected to see high GMV growth [2][20]. - Companies anticipated to show marginal improvements in performance include Proya, Marubi, and Ruifucheng [2]. - In the medical aesthetics sector, the report highlights Aimeike as a key recommendation, with Longzi suggested for further observation [2]. Market Trends - The domestic market share of leading brands is increasing, with the top ten domestic brands capturing 16.6% of the market share in skincare, up from 11.8% in 2023 [4]. - The report notes that the cosmetics retail sales in October 2025 grew by 9.6% year-on-year, indicating a recovery in demand driven by promotional events [10][11].

行 业 及 产 业 美容护理 2025 年 11 月 23 日 需求端稳健发展，业绩端分化加剧 看好 ——美容护理行业 25Q3 业绩回顾 本期投资提示： 研 究 / 行 业 点 评 聂霜 A0230524120002 nieshuang@swsresearch.com 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 相关研究 证 券 研 究 报 告 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 王盼 A0230523120001 wangpan@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 联系人 行 业 - ⚫ 25Q3 需求端淡季不淡，国货概念与个护崛起持续发力。据国家统计局，7-9 月化妆品 社会零售额 982 亿元，同比高个位数增长，相比 25H1 增长提速。同时大促带动 10 月 继续高增长，增速超 9%，跑赢社零整体。在需求端回暖背景下，国货崛起概念持续， 25 年双 11 大促，珀莱雅卫冕天猫渠道美妆 GMV 销售榜 TOP1， ...

Investment Rating - The report maintains a "Positive" investment rating for the retail industry [1] Core Insights - The retail industry is experiencing a significant transformation, with a focus on emotional consumption and innovative product offerings driving growth [6][32] - Companies like Liufu Group and Meili Tianyuan are implementing strategic upgrades to enhance brand value and market presence [27][29] Summary by Sections Retail Market Overview - The retail index reported a decline of 7.24% during the week of November 17-21, 2025, underperforming the Shanghai Composite Index by 3.34 percentage points [5][14] - The retail index has increased by 0.58% year-to-date, lagging behind the overall market performance [14][18] Company Performance Highlights - Liufu Group anticipates a revenue increase of approximately 20%-30% and a net profit growth of 40%-50% for the six months ending September 30, 2025, driven by effective product differentiation and sales strategies [27] - Meili Tianyuan is focusing on three major strategic initiatives: building a super brand through acquisitions, establishing a super chain for quality growth, and enhancing digital capabilities for precise marketing [29] Investment Themes - **Gold and Jewelry**: Focus on brands with differentiated product offerings and consumer insights, recommending companies like Laopuhuang and Chaohongji [6][35] - **Offline Retail**: Emphasize companies adapting to market changes, recommending Yonghui Supermarket and Aiyingshi [6][32] - **Cosmetics**: Highlight domestic brands that cater to emotional value and safety innovations, recommending companies like Maogeping and Pola [6][33] - **Medical Aesthetics**: Target differentiated product manufacturers and expanding medical chains, recommending Aimeike and Kedi-B [6][34] Key Company Updates - Chaohongji reported a revenue increase of 28.4% year-to-date, with a focus on expanding its franchise model and product innovation [38][40] - Yonghui Supermarket's revenue decreased by 22.2% year-to-date, but the company is undergoing a transformation to improve its supply chain and store optimization [41][43]

Core Viewpoint - Aimeike, once a leading player in the medical beauty industry, is facing significant challenges with declining performance and ongoing disputes over product agency rights, prompting a recent board reshuffle to address these issues [2][3][20]. Company Overview - Aimeike's actual controller, Jian Jun, has been re-elected as chairman, with a stable core management team, while the new board secretary, Li Dongmei, is seen as a fresh face amid the company's current challenges [2]. - The company has experienced a dramatic decline in performance, with a first-time negative growth reported in the first half of 2025, and significant year-on-year drops in revenue and net profit [3][13]. Financial Performance - In the third quarter of 2025, Aimeike reported revenue of 566 million yuan and a net profit of 304 million yuan, representing declines of 21.27% and 34.61% year-on-year, respectively [3]. - As of November 21, 2025, Aimeike's stock price is 148 yuan per share, with a market capitalization of 44.8 billion yuan, down over 100 billion yuan from its peak [4]. - The company's financial struggles have also impacted Jian Jun's wealth, which has decreased significantly over the past two years [6]. Historical Growth Trajectory - Aimeike's growth trajectory has been closely tied to its innovative product development, with significant milestones including the launch of its first self-developed product in 2009 and the introduction of several key products that drove revenue growth [9][10]. - The company saw explosive growth from 2021 to 2023, with revenues increasing from 1.448 billion yuan in 2021 to 2.869 billion yuan in 2023, and net profits rising from 958 million yuan to 1.858 billion yuan during the same period [7][10]. Current Challenges - The company is now facing a decline in growth momentum, with projections for 2024 showing single-digit growth rates, and a significant drop in revenue and net profit in the first half of 2025 [13]. - The decline is attributed to the weakening performance of its core products, particularly the HiTi and Luhua Tianzi, which have seen substantial year-on-year revenue declines [13][14]. Market Competition - The competitive landscape in the medical beauty industry is intensifying, with new entrants and increased product offerings leading to a dilution of Aimeike's previous competitive advantages [14][19]. - The recent launch of competing products has further pressured Aimeike's market share, particularly in the neck wrinkle treatment segment [13][14]. Strategic Responses - In response to these challenges, Aimeike is focusing on diversifying its product offerings and enhancing its research and development capabilities, including the introduction of new products and expansion into biopharmaceuticals [15][17]. - The company has also pursued strategic acquisitions, such as the purchase of a majority stake in REGEN, to bolster its product portfolio and enhance its competitive position in the global market [17][18]. Agency Dispute - Aimeike is embroiled in a significant dispute over the agency rights for its AestheFill product, which has led to legal actions and could impact its market performance [18][20]. - The resolution of this dispute is critical for Aimeike's management team, as it seeks to stabilize the company amid declining market conditions and increasing competition [20].

Core Viewpoint - Aimeike, once a leading player in the medical beauty industry, is facing significant challenges with declining performance and ongoing disputes over product agency rights, prompting a leadership change and strategic reassessment [4][6][20]. Company Overview - Aimeike's stock price peaked at 1331 yuan in February 2021, with a market capitalization exceeding 150 billion yuan, earning it the nickname "the Moutai of women" [4]. - The company has seen a dramatic decline in performance, with a 21.27% drop in revenue and a 34.61% drop in net profit in Q3 2025 compared to the previous year [6][8]. Financial Performance - Aimeike's financial performance over the past five years shows a significant decline, with 2025 projections indicating a drop in revenue and net profit by over 20% [9][13]. - The company's revenue and net profit for 2025 are expected to be 18.65 billion yuan and 10.93 billion yuan, respectively, marking a substantial decrease from previous years [9][13]. Product Development and Market Position - Aimeike's growth was initially driven by innovative products like the "Hi Body" and "Moisturizing Angel," which captured significant market share [10][11]. - However, competition has intensified, particularly in the high-end segment, leading to a dilution of the unique advantages of core products [12][14]. Strategic Response - In response to market challenges, Aimeike is diversifying its product offerings and has initiated a shift towards biopharmaceuticals and chemical drugs [15]. - The company has also pursued acquisitions, such as the purchase of a majority stake in REGEN, to enhance its product portfolio and market competitiveness [17][18]. Agency Dispute - Aimeike is embroiled in a significant dispute over the agency rights for its product AestheFill, which has implications for its market strategy and financial performance [18][19]. - The resolution of this dispute is critical for Aimeike's management to demonstrate their capability to navigate challenges and restore growth [20].

Core Viewpoint - Aimeike, once a leading player in the medical beauty industry, is facing significant challenges with declining performance and ongoing disputes over product agency rights, leading to a critical management transition [1][2]. Group 1: Company Performance - In the first half of 2025, Aimeike reported its first negative growth, with Q3 revenue at 566 million yuan and net profit at 304 million yuan, down 21.27% and 34.61% year-on-year, respectively [2]. - The company's market capitalization has dropped to approximately 45 billion yuan, a decline of over 100 billion yuan from its peak [2]. - The core products, including the solution-based injection products and gel-based injection products, have seen revenue declines of 23.79% and 23.99% respectively in the first half of 2025 [6]. Group 2: Management Changes - The recent board reshuffle saw Jian Jun re-elected as chairman, while the resignation of the board secretary, Jian Yong, and the appointment of Li Dongmei as the new secretary raised market interest [1][2]. - The new management faces the challenge of addressing the company's declining performance and resolving the ongoing agency disputes [2][12]. Group 3: Product Development and Market Dynamics - Aimeike's growth was initially driven by innovative products, such as the first domestically developed hyaluronic acid injection, which captured significant market share [3][4]. - The company has expanded its product matrix, with gel-based products showing substantial growth, achieving revenue of 1.158 billion yuan in 2023, a year-on-year increase of 81.43% [5]. - However, increased competition in the medical beauty sector has diluted the uniqueness of Aimeike's core products, leading to a more challenging market environment [6][7]. Group 4: Strategic Initiatives - Aimeike is pursuing diversification in its product offerings, including the launch of new products like the medical-grade polyethylene glycol gel [8]. - The company has also engaged in strategic acquisitions, such as the 190 million USD purchase of a majority stake in REGEN, to enhance its product portfolio and market competitiveness [9][10]. Group 5: Agency Disputes - Aimeike is embroiled in a significant agency dispute over the AestheFill product, which has implications for its market strategy and financial performance [10][11]. - The conflict escalated with the termination of the exclusive distribution agreement by Jiangsu Wuzhong, leading to potential legal ramifications and financial claims [11][12]. - The resolution of this dispute is critical for Aimeike's management to demonstrate its capability to navigate challenges and restore growth [13].

[Table_Title] 研究报告 Research Report 21 Nov 2025 爱美客 Imeik Technology Development (300896 CH) 25Q3 短期业绩承压，看好创新品种落地及出海 Short-term performance under pressure in 25Q3, optimistic about the launch of innovative products and overseas expansion 孟科含 Kehan Meng 孙旭东 Xudong Sun kh.meng@htisec.com xd.sun@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件 爱美客发布 2025Q3 业绩。 点评 受消费环境影响收入短期相对承压。2025Q3，公司实现收入 5.7 亿元（-21.3%），实现归母净利润 3.0 亿元 （-34.6%），扣非归母净利润 2.5 亿元（-42.4% ...

（文章来源：证券日报） 证券日报网讯爱美客11月21日在互动平台回答投资者提问时表示，截至2025年11月20日，公司股东人数 为60，941户。 ...